Lori Wirth, MD, reviews real-world and clinical trial data on treatment of advanced radioactive iodine-refractory differentiated thyroid cancer (RAI-R-DTC) with lenvatinib, and her personal experience with lenvatinib in clinical practice.
EP. 1: Real-World Outcomes Data on Lenvatinib as Monotherapy in Patients with RAI-R-DTC
Dr Lori Wirth reviews real-world outcomes data on lenvatinib treatment in patients with RAI-R-DTC and how they compare to the SELECT trial.
EP. 2: NCCN Guideline Updates on Lenvatinib for the Treatment of Advanced RAI-R-DTC
Dr Wirth reviews the updated NCCN guidelines that gave lenvatinib a category 1 recommendation for first-line treatment in advanced RAI-R-DTC and shares her experience of lenvatinib in clinical practice.
EP. 3: Managing Adverse Events of Lenvatinib in Patients with RAI-R-DTC
A key opinion leader explains the adverse events usually seen with lenvatinib treatment in patients with RAI-R-DTC, and the best management strategies.
EP. 4: Treatment Options for Advanced RAI-R-DTC After Progression on Lenvatinib
Lori Wirth, MD, describes the available treatment options for patients with advanced RAI-R-DTC who progress after first-line treatment with lenvatinib.
EP. 5: Investigational Agents and Ongoing Clinical Trials in Advanced RAI-R-DTC
Dr Lori Wirth highlights exciting clinical trials in advanced RAI-R-DTC and investigational agents to look out for in the future.
EP. 6: An Overview of Advanced Radioactive Iodine-Refractory Differentiated Thyroid Cancer (RAI-R-DTC)
Lori Wirth, MD, provides a brief overview of advanced radioactive iodine-refractory differentiated thyroid cancer, or RAI-R-DTC.
2 Clarke Drive Cranbury, NJ 08512